167 related articles for article (PubMed ID: 29022427)
1. Confirming the timing of phase-based costing in oncology studies: a case example in advanced melanoma.
Atkins M; Coutinho AD; Nunna S; Gupte-Singh K; Eaddy M
J Med Econ; 2018 Feb; 21(2):212-217. PubMed ID: 29022427
[TBL] [Abstract][Full Text] [Related]
2. Estimation of Direct Melanoma-related Costs by Disease Stage and by Phase of Diagnosis and Treatment According to Clinical Guidelines.
Buja A; Sartor G; Scioni M; Vecchiato A; Bolzan M; Rebba V; Sileni VC; Palozzo AC; Montesco M; Del Fiore P; Baldo V; Rossi CR
Acta Derm Venereol; 2018 Feb; 98(2):218-224. PubMed ID: 29110018
[TBL] [Abstract][Full Text] [Related]
3. Melanoma costs: a dynamic model comparing estimated overall costs of various clinical stages.
Alexandrescu DT
Dermatol Online J; 2009 Nov; 15(11):1. PubMed ID: 19951637
[TBL] [Abstract][Full Text] [Related]
4. Direct economic burden of high-risk and metastatic melanoma in the elderly: evidence from the SEER-Medicare linked database.
Davis KL; Mitra D; Kotapati S; Ibrahim R; Wolchok JD
Appl Health Econ Health Policy; 2009; 7(1):31-41. PubMed ID: 19558193
[TBL] [Abstract][Full Text] [Related]
5. The burden of metastatic melanoma: treatment patterns, healthcare use (utilization), and costs.
Reyes C; DaCosta Byfield S; Linke R; Satram-Hoang S; Teitelbaum AH
Melanoma Res; 2013 Apr; 23(2):159-66. PubMed ID: 23370422
[TBL] [Abstract][Full Text] [Related]
6. Economic impact of healthcare resource utilisation patterns among patients diagnosed with advanced melanoma in the United Kingdom, Italy, and France: results from a retrospective, longitudinal survey (MELODY study).
Johnston K; Levy AR; Lorigan P; Maio M; Lebbe C; Middleton M; Testori A; Bédane C; Konto C; Dueymes A; Sbarigia U; van Baardewijk M
Eur J Cancer; 2012 Sep; 48(14):2175-82. PubMed ID: 22480965
[TBL] [Abstract][Full Text] [Related]
7. Healthcare costs in patients with advanced non-small cell lung cancer and disease progression during targeted therapy: a real-world observational study.
Skinner KE; Fernandes AW; Walker MS; Pavilack M; VanderWalde A
J Med Econ; 2018 Feb; 21(2):192-200. PubMed ID: 29041833
[TBL] [Abstract][Full Text] [Related]
8. The economic burden of end-of-life care in metastatic breast cancer.
Bramley T; Antao V; Lunacsek O; Hennenfent K; Masaquel A
J Med Econ; 2016 Nov; 19(11):1075-1080. PubMed ID: 27248201
[TBL] [Abstract][Full Text] [Related]
9. Economic burden of melanoma in the elderly population: population-based analysis of the Surveillance, Epidemiology, and End Results (SEER)--Medicare data.
Seidler AM; Pennie ML; Veledar E; Culler SD; Chen SC
Arch Dermatol; 2010 Mar; 146(3):249-56. PubMed ID: 20231494
[TBL] [Abstract][Full Text] [Related]
10. Estimating healthcare resource use associated with the treatment of metastatic melanoma in eight countries.
McKendrick J; Gijsen M; Quinn C; Barber B; Zhao Z
J Med Econ; 2016 Jun; 19(6):587-95. PubMed ID: 26823114
[TBL] [Abstract][Full Text] [Related]
11. Melanoma treatment costs: a systematic review of the literature, 1990-2011.
Guy GP; Ekwueme DU; Tangka FK; Richardson LC
Am J Prev Med; 2012 Nov; 43(5):537-45. PubMed ID: 23079178
[TBL] [Abstract][Full Text] [Related]
12. The economic burden of lung cancer and the associated costs of treatment failure in the United States.
Kutikova L; Bowman L; Chang S; Long SR; Obasaju C; Crown WH
Lung Cancer; 2005 Nov; 50(2):143-54. PubMed ID: 16112249
[TBL] [Abstract][Full Text] [Related]
13. Health Care Resource Utilization and Associated Costs Among Metastatic Cutaneous Melanoma Patients Treated with Ipilimumab (INTUITION Study).
McArthur GA; Mohr P; Ascierto PA; Arance A; Banos Hernaez A; Kaskel P; Weichenthal M; Shinde R; Stevinson K
Oncologist; 2017 Aug; 22(8):951-962. PubMed ID: 28526721
[TBL] [Abstract][Full Text] [Related]
14. Economic burden of brain metastases among patients with metastatic melanoma in a USA managed care population.
Vekeman F; Cloutier M; Yermakov S; Amonkar MM; Arondekar B; Duh MS
Melanoma Res; 2014 Dec; 24(6):602-10. PubMed ID: 24926818
[TBL] [Abstract][Full Text] [Related]
15. An estimate of the annual direct cost of treating cutaneous melanoma.
Tsao H; Rogers GS; Sober AJ
J Am Acad Dermatol; 1998 May; 38(5 Pt 1):669-80. PubMed ID: 9591809
[TBL] [Abstract][Full Text] [Related]
16. Burden and treatment patterns of advanced basal cell carcinoma among commercially insured patients in a United States database from 2010 to 2014.
Migden M; Xie J; Wei J; Tang W; Herrera V; Palmer JB
J Am Acad Dermatol; 2017 Jul; 77(1):55-62.e3. PubMed ID: 28392293
[TBL] [Abstract][Full Text] [Related]
17. Is sex an independent prognostic factor in cutaneous head and neck melanoma?
Arce PM; Camilon PR; Stokes WA; Nguyen SA; Lentsch EJ
Laryngoscope; 2014 Jun; 124(6):1363-7. PubMed ID: 24122966
[TBL] [Abstract][Full Text] [Related]
18. An estimate of the cost of treating melanoma disease in the state of Sao Paulo - Brazil.
Souza RJ; Mattedi AP; Rezende ML; Corrêa Mde P; Duarte EM
An Bras Dermatol; 2009 Jul; 84(3):237-43. PubMed ID: 19668936
[TBL] [Abstract][Full Text] [Related]
19. Nail apparatus melanoma: A comparative, clinicoprognostic study of the initial clinical and morphological characteristics of 49 patients.
Lee WJ; Lee JH; Won CH; Chang SE; Choi JH; Moon KC; Lee MW
J Am Acad Dermatol; 2015 Aug; 73(2):213-20. PubMed ID: 26028523
[TBL] [Abstract][Full Text] [Related]
20. The economic burden of melanoma in France: assessing healthcare use in a hospital setting.
Chevalier J; Bonastre J; Avril MF
Melanoma Res; 2008 Feb; 18(1):40-6. PubMed ID: 18227707
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
